Heparan sulfate proteoglycan metabolic process

Across TCGA pan-cancer cohorts, RNA activity of the Heparan sulfate proteoglycan metabolic process pathway differs between tumor and matched normal tissue in 14 of the 18 cancer types tested.

The strongest signal is observed in colon adenocarcinoma (COAD), where pathway activity is higher in tumor tissue than in matched normal tissue. In most cancer types, this pathway shows higher activity in tumors, although a few cancer types, such as LIHC, show the opposite pattern, with lower activity in tumor tissue.

COAD, LUAD, and LUSC show the most reproducible tumor–normal differences in pathway activity.

Tumor vs normal pathway activity by lineage

Ranked by sampling consensus. Activity change represents the tumor-versus-normal difference in pathway activity on a log₂ scale. Positive values indicate higher pathway activity in tumor tissue. The reported p-values are derived from the corresponding differential activity tests.

Lineage	Gender	Stage	Activity change	p	Sampling consensus
COAD	Male	II,III,IV	+0.095	<.001	11	view →
LUAD	Female	III,IV	+0.117	<.001	9	view →
LUSC	All	II,III,IV	+0.065	<.001	8	view →
KIRC	Male	II,III,IV	+0.051	<.001	8	view →
KIRP	Male	All	+0.092	<.001	6	view →
STAD	All	All	+0.058	<.001	5	view →
LIHC	Male	All	−0.055	<.001	5	view →
BLCA	All	All	+0.039	.019	5	view →
READ	All	All	+0.082	.004	4	view →
BRCA	All	II,III,IV	+0.018	.004	4	view →
KICH	All	All	+0.038	.011	3	view →
ESCA	Female	All	+0.123	.004	2	view →

Pink = more active in tumor, green = less active in tumor. Showing the 12 strongest of 14 lineages.

GO:0030201–COAD

Open the COAD breakdown →